16 July 2018
Concepta PLC (AIM:CPT), the UK healthcare company and developer of a proprietary product targeted at the mobile health market and with a primary focus on women's fertility is pleased to announce the following Board changes.
Matthew Walls has been appointed as Chairman of the Board with immediate effect. Adam Reynolds, currently Chairman, will move to the role of Non-Executive Director.
Matthew brings extensive senior and board-level experience in public companies, particularly in pharmaceutical, diagnostics and biotech businesses. Matthew was most recently Chief Executive Officer and Chairman of the leading international patient behavioural change company, Atlantis Healthcare Group from 2015 until 2018.
Matthew has held Chairman and advisory roles since 2013 for The Fertility Partnership, which has grown to become the UK's largest fertility group; Matthew was previously Non-Executive Director and Chairman of Artificial Intelligence start-up, BioBeats Group Limited from 2016 until 2018; and Chief Executive Officer of AIM-listed molecular diagnostics company Genedrive Plc between 2007 and 2015, where he led the admission of the Company to AIM with the Company attaining 'Technology Company of the Year' in 2009 and 2015.
Matthew has also held the role of Chief Executive Officer at Oxford Biosignals Limited, Internexus Group Limited and Supanet Limited, and Zylepsis Limited between the years of 2000 and 2006 and was previously Global Commercial Director at the biopharmaceutical company AstraZeneca Plc where he was commercially and financially responsible for strategy and international business operations.
The Board also announces that Peter Dines has been appointed as Non-Executive Director with immediate effect. Peter currently holds the role of Chief Operating Officer & Head of Life Sciences and Biosciences at Mercia Technologies, Concepta's major shareholder. Peter has over two decades' experience in the healthcare sector having founded and run a number of successful healthcare technology businesses. Notable successes during his career include his time at orthopaedic and obstetrics equipment firm Surgicraft, and founder of spinal implant company Surgi C, a company that saw sales quadruple under his leadership. Finally, Dr Mark Wyatt has stepped down from his role as Non-Executive Director with immediate effect to focus on his other business interests.
Commenting on the Board changes, Erik Henau, Chief Executive Officer, said:
"We are thrilled to welcome Matthew Walls, who brings with him a wealth of experience in developing and leading both international pharma and healthcare groups, and SME companies. His fantastic track record in achieving commercial success and knowledge of corporate governance, regulatory issues, and delivery of strategic plans in the healthcare arena will be instrumental to Concepta as it enters this important phase in its expansion.
"Further, we are delighted to welcome Peter Dines as a Non-Executive Director. With over 20 years' experience in managing growth businesses in the healthcare and pharma sector, Peter will be a welcome addition to the Board and will further strengthen our team as we continue to scale the business.
"On behalf of the Board, I would like to thank Adam Reynolds for being instrumental to Concepta's AIM listing in 2016 and the contribution he has made in his role as Chairman since then. We are delighted that he will remain on the Board as Non-Executive Director. We would also like to thank Dr Mark Wyatt for his valuable service to the Board of Directors and we wish him every success in his future roles."
AIM Rules Disclosures
Save for the information above and below, there are no further disclosures to be made in accordance with Rule 17, Schedule 2(g) of the AIM Rules for Companies in respect of the appointment of Matthew Walls
Full name: Matthew Heaton Walls
Age: 54 years old
Matthew Walls is, or has during the last five years, been, a director of the following companies:
Past 5 years
Atlantis Healthcare Group Limited
BioBeats Group Limited
Reprogenetics UK Limited
Save for the information above and below, there are no further disclosures to be made in accordance with Rule 17, Schedule 2(g) of the AIM Rules for Companies in respect of the appointment of Peter Dines
Full name: Peter Michael Dines
Age: 45 years old
Peter Dines is, or has during the last five years, been, a director of the following companies:
Past 5 years
Mercia Fund Management Limited
Digital Life Sciences Limited
Mercia Growth Nominees Limited
Digital Life Sciences Group Limited
Mercia Growth Nominees 3 Limited
Mercia Growth Nominees 4 Limited
Bishop Veseys Grammar School
Mercia Growth Nominees 8 Limited
Mercia Digital Nominees Limited
Mercia Growth Nominees 7 Limited
University Growth Fund Nominees Limited
The Clive and Sylvia Richards Charity
Mercia Fund Management (Nominees) Limited
WM AHSN SME General Partner Limited
Diagnostic World Limited
C7 Ventures Limited
Mr Dines was appointed company director of Digital Life Sciences Limited, a provider of digital technology and consultancy solutions to the NHS, which is currently undergoing a creditors' voluntary liquidation with a preferential creditors' shortfall of £34,488. A voluntary liquidator was appointed on 24th Jan 2017 and the liquidators' statement was posted March 2018. Mr Dines was the largest creditor to the business due to loans provided by the parent company. There were no criticisms/findings against Mr Dines in relation to this case
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550
NOVUM Securities Limited (Broker)
Tel: +44 (0) 20 7399 9400
Yellow Jersey (Financial PR)
Georgia Colkin / Joe Burgess / Katie Bairsto
Tel: +44 (0) 776 932 5254
Notes to Editors
Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility† in women.
myLotus is currently the only consumer product which allows both quantitative and qualitative home test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus is to help women conceive naturally.
Concepta has made significant progress recently, establishing relationships with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future.
The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H2 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.
†Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.